Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)

Interested in this Trial?

Contact Us

Trial Status Completed

Trial Identifier

NCT01415427

Condition

MPS IVA, Mucopolysaccharidosis IV A, Morquio A Syndrome

The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. and has not been edited.

Trial Summary

This Phase 3 extension study will evaluate the long-term efficacy and safety of BMN 110 2.0 mg/kg/week and/or BMN 110 2.0 mg/kg/every other week in patients with mucopolysaccharidosis IVA (Morquio A Syndrome).

Eligibility Criteria

Birth Sex

All

Age

From 5 Years

Healthy Volunteers

No

Drug/Treatment:

BMN 110 - Weekly, BMN 110 - Every Other Week

Phase:

Phase 3

Study Type:

Interventional

Number of Participants:

173

Study Started:

2011-07

Study Updated:

2021-07-21

Trial Locations

  • Phoenix, Arizona, United States

  • Oakland, California, United States

  • Orange, California, United States

  • Wilmington, Delaware, United States

  • Washington, District of Columbia, United States

  • Orlando, Florida, United States

  • Honolulu, Hawaii, United States

  • Chicago, Illinois, United States

  • New York, New York, United States

  • Seattle, Washington, United States

  • Cordoba, , Argentina

  • Campina Grande, , Brazil

  • Porto Alegre, , Brazil

  • Rio de Janeiro, , Brazil

  • Montreal, , Canada

  • Sherbrooke, , Canada

  • Toronto, , Canada

  • Bogota, , Colombia

  • Copenhagen, , Denmark

  • Lyon, , France

  • Marseille, , France

  • Paris, , France

  • Paris, , France

  • Mainz, , Germany

  • Monza, , Italy

  • Tokyo, , Japan

  • Seoul, , Korea, Republic of

  • Amsterdam, , Netherlands

  • Oslo, , Norway

  • Coimbra, , Portugal

  • Lisbon, , Portugal

  • Doha, , Qatar

  • Riyadh, , Saudi Arabia

  • Santiago de Compostela, , Spain

  • Taipei, , Taiwan

  • Ankara, , Turkey

  • Belfast, , United Kingdom

  • Birmingham, , United Kingdom

  • Birmingham, , United Kingdom

  • London, , United Kingdom

  • London, , United Kingdom

  • London, , United Kingdom

  • Manchester, , United Kingdom

Inclusion Criteria

  • Must have completed MOR-004
  • Is willing and able to provide written, signed informed consent. Or in the case of patients under the age of 18 (or other age as defined by regional law or regulation), provide written assent (if required) and have written informed consent, signed by a legally authorize representative, after the nature of the study has been explained, and prior to performance of research-related procedures.
  • If sexually active, must be willing to use an acceptable method of contraception while participating in the study.
  • If female, of childbearing potential, must have a negative pregnancy test at Baseline and be willing to have additional pregnancy tests done during the study.

Exclusion Criteria

  • Is pregnant or breastfeeding, at Baseline, or planning to become pregnant (self or partner) at any time during the study.
  • Has used any investigational product (other than BMN 110 in MOR-004), or investigational medical device, within 30 days prior to Baseline; or is required to use any investigational agent prior to completion of all scheduled study assessments.
  • Was enrolled in a previous BMN 110 study, other than MOR-004.
  • Has a concurrent disease or condition, including but not limited to, symptomatic cervical spine instability, clinically significant spinal cord compression, or severe cardiac disease that would interfere with study participation, or pose a safety risk, as determined by the Investigator.
  • Has any condition that, in the view of the Investigator, places the patient at high risk of poor treatment compliance or of not completing the study

Contact BioMarin Clinical Trials

Please complete and submit the following form to express interest in participating and request more information about one of our clinical trials.

By completing this form and clicking the send button, you understand and hereby consent to storage of your personal information, including within the United States and Europe, which will be accessible by BioMarin for purposes such as responding to your request, quality control, fulfilling compliance obligations, and assisting with products, services, or clinical trials. Depending on where you live, you may have the right to request access to, removal, or correction of your personal information held by BioMarin. You may submit your request via the contact information and/or webform located within the full BioMarin Privacy Policy.

*required fields

"*" indicates required fields

This field is hidden when viewing the form
This field is hidden when viewing the form